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ABSTRACT 
Dendritic cells (DC) capture microorganisms that enter peripheral mucosal tissues and 
then migrate to secondary lymphoid organs, where they present these in antigenic form 
to resting T cells and thus initiate adaptive immune responses. A DC-specific C-type 
lectin, DC-SIGN, is highly expressed on DC present in mucosal tissues and binds to the 
HIV-1 envelope glycoprotein gp120. DC-SIGN efficiently captures HIV-1 in the 
periphery through a terminal carbohydrate recognition domain (CRD).
1 
The main 
carbohydrate ligand recognized by DC-SIGN is the high mannose glycan 
Man9(GlcNAC)2, a branched oligosaccharide presented in multiple copies by several 
pathogen glycoproteins. In the branched oligosaccharide, the terminal disaccharide 
portion Manα1-2Man binds DC-SIGN almost as efficiently as the entire high mannose 
glycan Man9(GlcNAc)2. This aspect suggests an important role of nonreducing end 
Manα1-2Man fragment of Man9 in DC-SIGN recognition
2
. 
Recently, it has been settled on a new class of DC-SIGN antagonists
2
: 
pseudodisaccharides in which the reducing mannose unit is replaced by a 
conformationally restricted dimethyl cycloexandicarboxylate. 
The main purpose of this thesis project is to operate a stereoselective synthesis of 
new DC-SIGN antagonist, characterized by the remarkable presence of a real D-
carbamannose unit with a hydrophobic portion, represented by a p-toluensulfonamide 
group at C(4) position. To build the pseudomannobioside, a new carbamannose unit, as 
glycosyl acceptor was connected to an appropriate glycosyl donor, represented by a 
manno-trichloroacetimidate (TCA) and the resulting pseudodisaccharide was subjected 
to different elaboration in order to obtain the desired pseudodisaccharides fully-O-
deprotected, with an ethoxy-amino chain on pseudo-anomeric position. 
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INTRODUCTION 
 
1. VIRAL PROTEINS AND SURFACE CARBOHYDRATES, TARGET OF DC-SIGN 
1.1 Structures of Viral Surface  
Enveloped viral particles usually contain different types of surface proteins the majority of which 
is modified by the addition of N-linked, O-linked carbohydrate chains or both. 
Typically, type I membrane proteins are characterized by a cleaved N-terminal signal peptide, a C-
terminal hydrophobic anchor sequence and a small C-terminal cytoplasmic domain. Type 2 proteins 
have an uncleaved N-terminal signal-anchor sequence and type 3 proteins with multiple membrane 
spanning domains also exist. However, the major proportion of such glycoproteins is usually 
situated on the external side of viral envelope. 
Totally viral envelope has shown to be extensively modified by N-linked glycosylation; however, 
the presence of O-linked carbohydrates on the glycoprotein has not been firmly established. N-
terminal attachment site is a constant region denoted principally by an Asn residue. Instead, Ser and 
Thr residues situated either in the proline-rich region of the molecule or in close proximity to the 
previous Asn, are shown to be O-glycosylated.
3
 
 
Knowledge of carbohydrate moieties linked to virus surface glycoproteins comes from a detailed 
structural analysis of some viruses having great biological and biomedical importance, such as 
Murine leukemia viruses, Marburg virus (MBGV), Hepatitis virus and finally as HIV. It 
demonstrates that specific N-glycosylation sites link above all high-mannose, hybrid or complex 
type di-, tri- and tetra-antennary N-glycans. The other carbohydrate constituents are represented by 
fucose and/or galactose residues (Table 1).
4 
To offer an idea of surface cell glycoproteins 
concentration, I take care above all of many studies covered on the human immunodeficiency virus 
type 1 (HIV-1) envelope glycoproteins.  
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1.1.1 The HIV-1 envelope glycoprotein  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 The HIV Env glycoprotein precursor, gp160, is a highly glycosylated protein of approximately 
850 amino acids. During intracellular transport, the gp160 polyprotein is cleaved into two subunits 
that remain associated: gp41, which contains ecto-, transmembrane, and cytoplasmic domains, and 
gp120, which is non-covalently linked to the ectodomain of gp41 (Figure 1.1). 
Figure 1.1 
Abstract 
 
 
  6 
The number of potential N-glycosylation sites on gp120 is on the order of 20, but the 
oligosaccharide structures are far more numerous. In fact, gp120 is extensively modified by N-
linked glycosylation as much as 50% of the molecular mass of the major envelope glycoprotein by 
carbohydrates in the form of oligosaccharide chains attached to the polypeptide backbone. Thus, it 
represents one of the most heavily glycosylated molecules in nature. 
 
1.1.2 Oligosaccharides on N-glycosylation sites 
Protein N-glycosylation is an important co-translational modification process wherein short sugar 
chains are covalently attached to the amide group of asparagine (N) residue in the amino acid chain. 
Although asparagine occurs frequently in the protein chain, N-glycosylation requires asparagine to 
be present in special motifs, in NXS/T sequons, the potential sites of N-glycosylation where X is any 
amino acid except proline which is avoided due to conformational hindrance and the third residue is 
either serine or threonine. Furthermore, N-glycosylation occurs only on some sequons found in 
membrane-bound or secretory proteins which are exposed to the enzyme oligosaccharyl-transferase 
in the lumen of endoplasmic reticulum. To know the number and distribution of N-glycosylated 
sequons, gp120 sequence is divided in two (N and C terminal) parts. Two rational methods are used: 
first, the gp120 has two parts namely the inner and outer domains. The bulk of the N terminal part of 
the sequence forms the inner domain and the C terminal part forms the outer domain. The amino 
acid chain makes a transition from inner to outer domain. Second, it is known that the two domains 
are unequally glycosylated with a higher proportion occurring in the outer domain. It may be 
thought that the outer domain is much more exposed to solvent and has a number of regions, which 
interact with host proteins as compared to the inner domain, much of it is facing gp41 or inner 
domains of gp120 monomers within the trimeric complex. Each monomer in non-covalent 
association with gp41, the transmembrane viral envelope glycoprotein anchor, interacts with its 
primary receptor CD4 glycoprotein of the host T-lymphocyte. 
Abstract 
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Some study found no significant change over time in the number of NXS/T sequons in the whole 
gp120 molecule, which contains an average of 26 NXS/T sequons. The gain or loss of sequons may 
influence the gp120/virus. For example, the glycan structures are quite bulky (~2000 Da) and 
therefore, the additional sequons may not provide a selective advantage due to conformational 
instability or functional redundancy. Similarly, the loss of sequons may have fitness costs, as they 
lead to failure of infectivity/immune evasion. In addition, in more variable regions of the envelope, 
amino acid exchanges may cause the addition or deletion of glycosylation site. It is hypothesized 
that simply under selection pressures, the gp120 must naturally undergo rapid changes with respect 
to its N-glycosylation sequons. For instance, under selection pressure by mannose-specific lectins, 
resistant HIV-1 strains showed marked depletion (up to eight out of 22) of the N-glycosylation 
sequons in gp120 regions distant from interacting sites. Fluctuations in the variable regions of the 
gp120 itself has been shown to change the N-glycosylation sequons in the early stages of viral 
infection. Likewise, it is reasonable to expect a long-term trend in the number of N-glycosylation 
sequons in gp120 under the selection pressure from the host immune system or anti-retroviral drugs 
since the passage of HIV to human hosts.
5
  
Finally, other studies show a very clear directional change in the density (or number) of sequons in 
the two domains of gp120. The NXT sequon density is decreasing in the outer domain and the NXS 
sequon density is increasing. The increase in NXS density is significant even when gp120 molecule 
is considered as a whole. But it is interesting to note that there is no net change in the NXT sequon 
density in the whole gp120 molecule. This is because the decrease in NXT density in outer domain 
is compensated by significant increase in NXT density in inner domain over the time period between 
1981 and 2009. It may be recalled that previous studies failed to notice these intricate trends, instead 
reported mere fluctuations in the sequon numbers in gp120 over time.  
Leaving out the changes regarding NXS/T sequons, some studies were addressed on recombinant 
gp120 produced in chronically infected T lymphocytes (H9 cells) and transfected Chinese hamster 
ovary (CHO) cells. A different structural characterization of carbohydrates sequences on gp120 was 
identified including high mannose-type (Man5 to Man9 structures amounting to -33%) and hybrid-
Abstract 
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type (4%) chains as well as four categories of complex-type chains (mono-, bi-, tri-, and 
tetraantennary) with or without N-acetyllactosamine repeats and with or without core region fucose 
residues among which digalactosyl biantennary structures predominated (34%). Altogether, 29 
structures were identified after desialylation.  
The process of N-linked glycosylation can result in diverse structures that may be divided into the 
three categories: oligomannose, hybrid, and complex. Each category shares a common 
Man3GlcNAc2 pentasaccharide stem (where Man is mannose and GlcNAc is N-acetylglucosamine), 
to which up to six mannose residues are attached in oligomannose N-glycans, while complex N-
glycans are usually larger and may bear various sizes and numbers of antennae. Glycan synthesis 
begins in the endoplasmic reticulum, where N-linked oligomannose precursors Glc3Man9(GlcNAc)2 
(Glc is glucose) are transferred cotranslationally to the free amide of the asparagine in a sequon 
Asn-X-Thr/Ser. 
The actual number of oligosaccharides is much greater: there was evidence that among the hybrid- 
and complex-type chains, all but 6% contained sialic acid at C-3 in terminal galactose residues, and 
partially sialylated forms of the bi- and multiantennary chains were present.  
The marked variability of the glycosylation details is considerably influenced by the host cell.
6
 The 
oligosaccharide profiles were compared for the envelope glycoproteins of different virus isolates 
that differ in their biological properties and amino acid sequences of their env genes. When the virus 
isolates were propagated in the same host cells, their N-glycan patterns were similar, whereas there 
were marked differences when propagated in different host cells. For example, the HIV-1 gp120 
produced in insect cells was found to have a repertoire of high mannose type but no complex type 
N-glycans. Instead, gp160, and so gp120, produced in the human lymphoblastoid cell line Molt-4 
demonstrated the presence of sulfate 6-linked to the N-acetylglucosamine of complex type chains.  
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1.1.3 Oligosaccharides on O-glycosilation sites 
There were several investigations of the presence of O-linked oligosaccharides on the HIV-1 
envelope glycoprotein, but it has not been conclusively established. O-linked glycosylation has been 
demonstrated, however, for other retroviral glycoproteins, including Friend spleen focus-forming 
virus (SFFV), Friend mink cell focus-forming virus (FrMCF), Rauscher murine leukemia virus (R-
MuLV), and feline leukemia virus. The O-linked carbohydrates were localized above all to the 
surface subunits of the FrMCF glycoproteins.  
O-linked glycosylation is a commonly occurring form of post-translational modification; so it begins 
with the addition of the core sugar GalNAc in an α-glycosidic linkage to a serine or threonine 
residue. The basic structure may then be enhanced by the subsequent addition of galactose, N-
acetylglucosamine, fucose, and sialic acid by glycosyltransferases found in the Golgi apparatus. The 
structures of O-linked carbohydrates are varied, and there is no common carbohydrate core or 
processing pathway similar to that involved in N-linked glycosylation.  
Indirect evidence supporting the presence of O-linked oligosaccharides on the HIV-1 envelope 
glycoprotein has previously been obtained: it was observed a difference in the pI between envelope 
glycoprotein that had been deglycosylated with PNGase F and envelope glycoprotein that had been 
treated with neuraminidase prior to deglycosylation with PNGase F, suggesting that sialated O-
linked carbohydrates may be present on the HIV-1 envelope glycoprotein. Our observation that 
treatment with neuraminidase followed by O-glycosidase causes a decrease in the apparent 
molecular weight of gpl20 and gpl60 correlates with their data and suggests that both the precursor 
and surface unit forms of the glycoprotein contain O-linked glycans. 
Likewise, immuno-precipitation experiments carried out with anticarbohydrate monoclonal 
antibodies demonstrate O-linked carbohydrates presence. These antibodies were found to 
immunoprecipitate gpl20 and inhibit infection and syncytium formation in CD4
+
 lymphocytic cell 
lines. However, the common O-linked sequence Galβ1-3GalNAc, with or without terminal sialic 
acid, could not be detected on natural gp120 derived from infected H9 cells, or on recombinant gp 
120 from CHO cells, a cell line which is reversibly defective in O-linked glycosylation because of 
its inability to synthesize UDP-Gal and UDP-GalNAc. As described before, glycosylation is host 
cell specific and is dependent on the presence of glycosyltransferases, which vary among different 
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cell types. In addition, variation in glycosylation may even be seen within a single cell line, as 
observed by Mizuochi et al.,
6
 who analyzed the N-linked carbohydrate structures present on the 
envelope glycoprotein of HIV-IIIB isolated from H9 cells.  
 
 
1.2  Functions of Viral Surface Glycoproteins 
Most viral envelope glycoproteins are essential during the viral life cycle. They permit virion’s 
assembly and defend it from enzymatic attack; but their key role in human is to induce a humoral 
immune response.  
First of all, it is necessary explain that target cells for viral glycoproteins are various: for example, 
HIV can infect CD4 T cell, macrophages and 
microglial cells. This is possible because viral 
glycoproteins chains are characterized by many 
moieties, each of which interacts with a specific cell 
receptor.  Our attention was focused on dendritic cell-
specific ICAM-3 grabbing nonintegrin (DC-SIGN) 
receptor that interacts with many viruses, as HIV, 
SIV, Ebola virus, Hepatitis C, Dengue, SARS, and 
also some bacteria (Mycobacterium tuberculosis, 
Helicobacter pylori). So, mediating the first contact 
with host cell receptor, virus binding and subsequent 
fusion of viral and cell membranes, glycoproteins 
direct starting infection. 
 Thus, virion can penetrate into the host cell, where 
makes its genome accessible for transcription. For some viruses, a single membrane glycoprotein is 
Figure 1.2 
A) Ribbon representation of gp41; 
B The exposure of aromatic side chains Trp 678, Trp 
680 and Tyr 681 towards the membrane. 
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responsible for both functions, whereas for others, receptor binding and fusion activities reside in 
different glycoproteins. For examples, Human Immunodeficiency Virus (HIV) envelope 
glycoproteins, gp120 and gp41 are both vital for virus entry into host cell: gp120 is essential for 
viral adhesion to specific surface receptors of various cell types, although gp41 interacts with the 
specific cell membrane in a second time. After conformational and position change of the first 
glycoprotein, gp41 (showed in Figure 1.2) allows the beginning of membranes fusion process and 
virion entry into host cell cytoplasm. 
However, attachment of an envelope glycoprotein to a cell surface requires a specific binding among 
viral polypeptide chain and host cellular receptor. In fact, the HIV-1 pathogenesis, to a large extent, 
has been attributed to the structural plasticity of the gp120, and in particular, to the variability of N-
glycosylation, that allows specific interactions.
7 
Since 1992, other studies have been focused on the influence of N-linked oligosaccharides on the 
transmembrane glycoprotein gp41of HIV-1 on viral infectivity. In the first investigations, some 
amino acid changes caused a severe impairment of viral infectivity toward a CD4-positive cell line; 
in the second of these, variable effects on infectivity toward different CD4-positive cells were 
observed particularly with respect to fusion activity. More recent investigations have reached the 
conclusion that the glycosylation site at position 621 is the most important for fusion activity, and 
that gp41 lacking N-glycans becomes arrested in the Golgi apparatus. From the observed results, 
lack of saccharides or critical change in the protein folding and conformation could direct the 
impairment of binding affinity.
8
  
 
1.2.1 Functions of Carbohydrate Substituents in N-glycosylation sites 
From recent studies, N-glycosylation is the prerequisite of a number of proteins properties such as 
solubility, stability and turnover, secretion, protease resistance, protein-protein 
interaction/recognition and immunogenicity, and hence has an immense biological importance. 
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The key role of these carbohydrates in protein function and immune recognition is that to mask the 
antigenicity of the polypeptide backbone; at the same time they guide the presentation of the whole 
glycoprotein to antigen- presenting cells.  
a. Glycosylation can influence the protein active form 
In order to determine which specific N-linked glycans are critical for envelope protein function or 
immune escape, several recent studies on HIV envelope glycoprotein have been directed from the 
Departments of Pathology, Cell Biology, and Immunobiology, Yale University School of Medicine of 
Connecticut on individual or multiple mutations of glycosylation site (as described above).
7a
 As 
result of peptide portion changes, the presence of a variety of carbohydrates is especially critical 
during early steps of envelope protein folding and cleavage, but once envelope achieves its final 
conformation, glycosylation is less critical. So, oligosaccharides at highly conserved N-
glycosylation sites appear to be important for the glycoprotein biologically active form. It is the 
prerequisite for suitable binding to the host cell receptors. 
b. Glycosylation can influence antigenicity and immunogenicity 
Carbohydrate-mediated reactivity of gp120 with two proteins of the host was documented thus far. 
The first is with the serum lectin known as mannose-binding protein, of which will be discussed in 
greater detail below. The second carbohydrate-mediated interaction, shown with gp120, is with the 
endocytosis receptor of human macrophage membranes. High affinity binding may lead to viral 
uptake by macrophages irrespective of the presence of the membrane-associated CD4 receptor. 
Some examples of antigenic determinants of the viral envelope include the accessible mannose or 
fucose residues, the N-acetylglucosamine or linear and branched poly-N-acetyllactosamine 
backbone sequences.  
Specific envelope glycosylation sites also appear to have an important role in modulating the 
antibody response.
9
  It is the outer domain, divided into a neutralizing face and an immunologically 
silent face: oligomannose glycans cluster tightly on the silent face of gp120, while complex glycans 
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flank the gp120 receptor binding sites of the neutralizing face, forming a protective “fence” against 
Nabs. 
For instance, a replace of N-linked glycan in the HIV-1BRU envelope V1 region can make the virus 
more resistant to neutralization by anti-V3 antibodies. Instead, HIV IIIB env clones lacking an N-
glycan in the V3 loop of envelope protein exhibited increased sensitivities to V3 loop-specific 
monoclonal antibodies (MAbs) and soluble CD4. By masking an immunodominant epitope in the 
V3 loop with additional N-linked carbohydrates, the antibody response can be shifted from the V3 
epitope to the V1 epitope. 
 One of the most dramatic effects of carbohydrate removal from an envelope glycoprotein was 
reported from many studies with simian immunodeficiency virus (SIV): these results indicated 
significant differences between SIV and HIV with regard to the roles of glycans. Most mutants, 
lacking of a number of N-linked glycosylation, induced a marked increase antibody and a marked 
increased neutralizing activity. These results, observed for example in infected Rhesus monkeys
10
, 
demonstrated a role for N-linked glycosylation in limiting the neutralizing antibody response to SIV 
and in shielding the virus from immune recognition. 
So, carbohydrates provide a layer of protection against NAb attack. As glycans are considered self, 
antibody responses against them are thought to be regulated by tolerance mechanisms.  
The relatively sparse clustering of complex glycans that form this fence may reflect a trade-off 
between protecting the underlying functional domains from NAbs thanks to the high density while 
at the same time permitting sufficient flexibility for the refolding events associated with receptor 
binding and fusion. Conversely, the dense clustering of oligomannose glycans on the silent domain 
may be important for ensuring immune protection and/or in creating binding sites for lectins such as 
DC-SIGN. 
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1.2.2  Functions of Carbohydrate Substituents in O-glycosylation sites 
The function of O-linked glycosylation is not well understood. Some studies proposed that the O-
glycosylation sites may play a role in the stability of cell surface glycoproteins, and prevent their 
proteolysis.  
A recent report by Overbaugh and Rudensky demonstrates that simian immunodeficiency virus 
variants isolated late in the progression to simian AIDS contain envelope sequences rich in serine 
and threonine, and they suggest that these changes may be accompanied by increased glycosylation, 
including potential sites for the addition of O-linked glycans. Such addition of oligosaccharides may 
play a role in escape of viruses from immune surveillance mechanisms by masking antigenic 
epitopes on the glycoprotein. But a specific role for these structures is yet to define.  
 
 
1.3  Immune response and interaction with target cells 
The human immunodeficiency viruses (HIV-1 and HIV-2) and simian immunodeficiency viruses 
(SIVs) are the etiologic agents of acquired immunodeficiency syndrome (AIDS) in their respective 
human and simian hosts.
10a
 
Typically, infection with primate immunodeficiency viruses is characterized by an initial phase of 
high-level viremia, followed by a long period of persistent virus replication at a lower level. Viral 
persistence occurs despite specific antiviral immune responses, which include the generation of 
neutralizing antibodies. 
The primate immunodeficiency viruses, like all retroviruses, are surrounded by an envelope 
consisting of a host cell lipid bilayer and virus-encoded envelope glycoproteins. Fusion process 
between these two membranes is very important to the viral evolution in the host. All the viral 
components are synthetized in the infected cell from genes and retroviral enzymes, coming from 
viral cells, and then are modified in the Golgi apparatus: gp160 is cleaved by a cellular protease 
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generating the mature envelope glycoproteins (gp120 and gp41), carbohydrates on the gp120 
glycoprotein are modified by the addition of complex sugar and then the assembly virion exit from 
the host cell. 
The exposed location of the proteins on the virus allows them to carry out their function but also 
renders them uniquely accessible to neutralizing antibodies. Thus, virus replication and immune 
response drive the evolution of the envelope glycoproteins and continue to do so within each 
infected host. 
Many cell surface proteins, including adhesion molecules, are incorporated into HIV-1 virions along 
with the envelope glycoprotein complexes. These host cell-derived molecules can assist the 
attachment of viruses to potential target cells. Virus attachment also involves the interaction of the 
gp120 envelope glycoproteins with specific receptors, as the CD4 glycoprotein and members of the 
chemokine receptor family. The CD4 glycoprotein is expressed on the surface of T lymphocytes, 
monocytes, dendritic cells, and microglia, the main target cells for primate immunodeficiency 
viruses in vivo. The adhesion to CD4 receptor is not the only one: among the viral attachment 
factors there is a C-type lectin, DC-specific intercellular adhesion molecule 3 (ICAM-3)-grabbing 
nonintegrin (DC-SIGN, also known as CD209), which mediates viral transmission with high affinity 
to the envelope glycans. Attachment to DC-SIGN thus enhances viral spread in mucosal dendritic 
cells and, by taking advantage of the inherent capacity of DCs to migrate into lymphoid tissue, 
might promote viral dissemination within the host. DC-SIGN and a related molecule, DC-SIGNR, 
also enhance infection by Ebola virus. DC-SIGN expression is restricted to certain dendritic cells 
subgroups, dermal and stromal DCs, and it is not expressed on follicular DCs or on skin-resident 
LCs. Other cell types that express DC-SIGN include monocyte-derived DCs (MDDCs), 
macrophages and activated B lymphocytes.  
Several weeks after virus infection, usually after the initial high level of viremia has decreased, 
neutralizing antibodies can be detected infected animals or humans. These antibodies neutralize the 
infecting virus, but often exhibit little or no activity against other strains of virus. A subset of these 
strain-restricted antibodies recognizes the HIV-1 V3 loop. These antibodies can block also 
chemokine receptor binding. 
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2. DC-SIGN AS TARGET RECEPTOR 
 
2.1 Structure and Function of DC-SIGN 
DC-SIGN belongs to calcium (Ca
2+
)-dependent lectin group, known as C-type lectins. It is a type II 
membrane protein with a single carbohydrate-recognition domain (CRD) represented by a C-terminal 
portion. Indeed, it is characterized by other three domains: the N-terminal cytoplasmic tail and 
transmembrane domain followed by the extracellular part composed of a neck region.
11
 
Lectins class that binds to exogenous sugars, includes the mannose-binding proteins (MBPs) and 
endocytic receptors, such as the macrophage mannose receptor that mediates the innate immune 
response against invading microorganisms by interacting with cell surface sugar structures. So, DC-
SIGN shares specificity for mannose and are involved in pathogen recognition.
12
  
Immature dendritic cells in mucosal tissue use DC-SIGN to recognize high-mannose glycans present 
on the viral envelope glycoprotein, as on gp120 of HIV. This recognition event appears to contribute to 
infection by promoting viral transmission in a manner dependent on the composition of gp120 glycans. 
So, DC-SIGN exists only at low levels on blood monocytes and when they leave blood to peripheral 
tissues the expression of this lectin is extremely increased. Finally, following DC maturation and 
migration to secondary lymphoid tissues, DC-SIGN levels are down-regulated. This detail of DC-SIGN 
is important to understand that the lectin doesn’t work as a receptor for viral entry into DC; instead 
binding of the viral envelope glycoprotein to DC-SIGN may induce a conformational change that 
enables a more efficient interaction with CD4 and/or chemokine receptor (CCR5) promoting 
resourceful infection.  
 
2.1.1 Structure of CRD and Calcium-mediated interaction 
The Ca
2+
-dependent CRD (Figure 1.3) of DC-SIGN is a long-form polypeptide sustained by four 
disulphide bridges. It contains two occupied calcium-binding sites, one of which is essential for the 
polypeptide tertiary structure and the other to coordinate ligand binding, as mannose group sugars. 
Abstract 
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Usually, the cation links amino acids and oxygen atoms from carbohydrates hydroxyl groups. 
Indeed, it can play a significant role in the stereospecific recognition of carbohydrates via the 
relative stereochemistry (cis or trans) of two adjacent 
hydroxyl groups. For instance hydroxyl groups 
corresponding to the 3- and 4-OHs of mannose serve 
as coordination ligands for the Ca
2+
. Additional 
coordination ligands are provided by asparagine and 
glutamic acid residues that also form hydrogen bonds 
with the 3- and 4-OH groups of the sugar and with C6-
position.  
Moreover, DC-SIGN binding site shows Val
351 
residue 
as the main amino acid residue that participates in 
carbohydrate binding through van der Waals interactions. 
In addition to the ligand interaction with the primary 
binding site centered around the Ca
2+ 
ion, the ligand forms additional contacts with the surface of DC-
SIGN.
13 
  
Recent studies as Cross-linking, Equilibrium Ultracentrifugation, and Circular Dichroism studies 
showed that the extracellular domain of each molecule is a tetramer (Figure 1.4) stabilized by an α-
helical neck. 
Figure 1.4 Schematic representation 
of lectin/pathogen interaction affinity increase due to the avidity phenomenon. 
Figure 1.3 Calcium-mediated interaction 
of a high mannose N-glycan (cyan) with 
the human DC-SIGN carbohydrate 
recognition domain (green/orange) 
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 Such individual CRD has high affinity for mannose-containing oligosaccharides. When the CRDs are 
clustered in the tetrameric extracellular domain, their arrangement provides a means of amplifying 
specificity for multiple high mannose oligosaccharides spaced at appropriate distances on the surface.
14
 
Mannan was the most potent inhibitor (IC50, 6,0 g/ml), followed by L-fucose (Ki, 6mM); α-methyl D-
mannoside (Ki, 15mM), D-mannose (Ki, 23mM); and N-acetylglucosamine (Ki, 70mM). Human IgE, 
sialic acid, and mannose 6-phosphate had no effect on binding: none affects gpl20 binding or gp120-C-
type lectin complex binding to CD4. 
 
2.1.2 Key Interaction for viral infection 
Most C-type lectins expressed by DC have specificity for mannose-containing carbohydrates. Usually, 
they recognizes a unique branching and positioning of mannose residues on cell-surface structure, 
whereas DC-SIGN may recognize high-mannose residues located more internally within a glycan 
structure and no single terminal mannose residues. This competency offers to DC-SIGN more 
possibility in the recognition of many pathogens.  
The process through which DC-SIGN promotes efficient infection in cells through their 
CD4/chemokine receptor complex is of particular interest. DC binds strongly to the adhesion molecule 
ICAM-3 through a veritable “immunological synapse”. 
ICAM-3, expressed constitutively on the surface of T lymphocytes, carries an abundance of N-linked 
high mannose oligosaccharides just as gp120. Enzymatic removal of N-linked carbohydrates from 
ICAM-3 abrogates its binding to DC-SIGN completely. Moreover, also ICAM-3 binding by DC-SIGN 
is Ca
2+
-dependent, main feature of C-type lectins that contain an extracellular CRD. The interaction of 
DC-SIGN with HIV-1, ICAM-2 and ICAM-3 is inhibited by mannan, mannose, and EGTA.  
This observation, deriving above all from many experiments with anti-DC-SIGN antibodies (AZN-D1 
and -D2), suggests that ICAM-3 and gp120 bind to similar or closely located, but different sites. 
DC-SIGN-ICAM-3 complex, followed by interactions through other adhesion molecules such as 
LFA-1 and LFA-3 which help in more stable DC–T cell contacts, plays an important role in the 
activation and proliferation of T cells.
15 
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In addition to multiple conformational transitions and interaction of DC-SIGN, crystal structure of a 
gp120-CD4 complex has revealed that most glycosylation sites within gp120 bind the CD4-binding 
pocket. So, it is likely that DC-SIGN binding site links to one or more carbohydrate moieties in gp120. 
It is possible, however, that this C-type lectin domain interacts also with the polypeptide backbone of 
gp120.  
 
2.1.3  Virus-DC-SIGN Complex Retains Infectivity for a long time 
After interaction with the multivalent virus particles, DCs may initiate their activation process. The 
time course experiment shows that DC-SIGN is able to capture and bind to HIV-1 for more than 4 
days, after which the virus can still infect permissive cells. This long-term preservation of HIV-1 in an 
infectious state would appear to allow sufficient time for it to be transported by DC trafficking from 
mucosal surfaces to lymphoid compartments, where virus can be transmitted.  
During their journey to the regional lymph nodes, DCs protect the viral particles within endocytic 
vesicles. But other studies are required to understand if this internalization is necessary for infectivity 
conservation. 
 
 
2.2  DC-SIGN Or Langerin As Host Receptor  
DC-SIGN and Langerin are both C-type lectins of dendritic cells. Equally, they have specificity for 
mannose and are involved in pathogen recognition. Whereas DC-SIGN allows transinfection of T cells 
after interaction with viral Env surface, Langerin, on the contrary, contributes to virus elimination. So, 
it has protective effects on the host cells. 
Selective ligands for DC-SIGN, which interact only weakly with Langerin, are potentially useful 
therapeutic tools against HIV infection. This is the purpose of the latest studies on the mannose- based 
glycomimetics used as DC-SIGN inhibitor.  
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2.3 DC-SIGN Or CD4 As Host Receptor 
In 2007, studies directed from Jian-Hua Wang and his group
16
 analyzed the dendritic cells (DCs) and 
their key role in the induction and regulation of adaptive immune response. They confirmed DCs are 
the first cells to encounter HIV at the mucosa, and also discovered that the co-expression of CD4 and 
DC-SIGN in Raji cells promoted the internalization and intracellular retention of HIV-1. These results 
suggest that CD4, presents at various levels in DC-SIGN-positive primary cells, is an important 
regulator of HIV-1 transmission.  The principally difference compared to DC-SIGN concerns actually 
the HIV replication, allowed only from CD4. 
Many flow cytometric adhesion assays have demonstrated the ability of HIV-1 coated gp120 to bind 
to immature DC. The gp120-coated glycans bound efficiently to the DC, and the binding was 
completely blocked by the anti-DC-SIGN antibodies AZN-D1 and AZN-D2. In contrast, neutralizing 
anti-CD4 antibodies had no effect on gp120 binding to DC. This result indicates that, although the 
primary HIV-1 receptor CD4 is expressed on DC, HIV-1 gp120 preferentially binds to DC-SIGN. It is 
demonstrated the potency of DC in initiating immune responses from resting T cells: small numbers of 
DCs, and relatively low doses of an antigen or other T cell stimulus, are sufficient to initiate rapid and 
strong responses, such as T cell proliferation and lymphokine production. 
This way, many studies demonstrated that DC-SIGN is a specific dendritic cell surface receptor for 
the HIV-1 envelope glycoprotein. Finally, DC-SIGN cannot be substituted for CD4 in the process of 
HIV-1 entry and innate immune response.
17 
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2.4 Monosaccharide Binding Activity 
Synthetic analyses of monosaccharides which interact with CRD of DC-SIGN are represented in 
the next Table 1
18
: 
DC-SIGN binds mannose residue better than they bind galactose, as expected from recent analysis of 
the CRD sequences. Binding of galactose to mannose-specific C-type CRDs can occur through 
interactions with the C-1 and C-2 hydroxyl groups of the free sugar. Interaction between mannose 
residues and DC-SIGN is through equatorial 3-OH and 4-OH groups and the overall binding is 
maintained by the hydrogen bond and can be mediated or not by water molecules.  
In a binding assay of various compounds with rat hepatic lectin and chicken hepatic lectin, the results 
suggest that the 3- and 4-OH of the target sugar are indispensable, while the 6-OH is not required. Both 
DC-SIGN and DC-SIGNR show preference for axial C-2 substituents, as they interact with glucose and 
GlcNAc more weakly than they interact with mannose. For both proteins, affinity was increased by 
replacement of the axial hydroxyl group of mannose with the N-acetyl group in N-acetylmannosamine.  
 
 
Table 1 
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2.4.1 High Affinity Binding to High Mannose Oligosaccharides 
Recent studies demonstrate that the interaction with high mannose ligands is not limited to terminal 
mannose residues and rather involves internal residues that stretch along the extended binding site. This 
aspect was observed in natural ligand interaction with DC-SIGN receptor: it can interact with high 
mannose-type oligosaccharides but not with single terminal mannose residue. 
The main carbohydrate ligand recognized by DC-SIGN is the natural high mannose glycan, 
Man9(GlcNAc)2, also represented as Man9, a branched oligosaccharide which is presented in multiple 
copies by several pathogen glycoproteins (gp120, GP1, etc.). The Man9(GlcNAc)2 oligosaccharide 
competes for binding to the extracellular domain of DC-SIGNR 24-fold more effectively than does 
mannose. Because the oligosaccharides on natural ligands for DC-SIGN include a range of high 
mannose structures, binding to these different species was compared by using the extracellular domains 
of DC-SIGN to probe neoglycolipids coated by high mannose oligosaccharides. Thus, the probe 
species from Man5(GlcNAc)2  to Man9(GlcNAc)2 gave satisfactory results, likely similar to interactions 
with natural ligand, including the Man6(GlcNAc)2  found on ICAM-3 isolated from human blood 
cells.
14a
 
Moreover, the increased affinity is often related to the formation of lectin oligomers (as described in 
paragraph 2.1.1) in which multiple CRDs bind to multiple terminal sugar residues in the ligands, and at 
the same time oligosaccharides make additional contacts with the beyond the primary mannose-binding 
site.  
 
2.4.2 Hydrophilic Or Hydrophobic Character Of Ligand 
When hydrophobic molecules interact with hydrated binding sites of these lectins, a favorable 
desolvation and establishment of hydrophobic stacking are often considered as the basis for the 
hydrophobic interactions. Even though carbohydrates are hydrophilic molecules, they also frequently 
establish hydrophobic interactions with lectins. Indeed, the two faces (α and β) of the pyranose ring 
display hydrophobic C–H bonds, which can engage in stacking interactions with protein aromatic side 
Abstract 
 
 
  23 
chains. It is thus common to observe “stacking” of these cycles with aromatic amino acids (Phe, Trp, 
Tyr), and these interactions are a powerful source of discrimination toward different carbohydrates.  
In addition, carbohydrates are generally neutral species, but some sugars (sialic, glucuronic and 
iduronic acids, aminosugars, alkylated-thiosugars) or modified-sugars (phosphorylated and sulfated 
sugars) can be either positively or negatively charged. Charged functional groups can give rise to 
additional contacts with lectins through ionic electrostatic interactions with charged residues.
12b
 
Finally, water molecules have a crucial role in carbohydrate–lectin binding events both as solvation 
molecules and as a relay in the establishment of hydrogen-bonding network. Hydrogen bonding 
through an intermediate water molecule is indeed quite frequent, and such a relayed hydrogen bond has 
a comparable energy. The desolvation of water molecules from both binding sites and carbohydrates 
ligand is very favorable entropically and is commonly invoked as an important driving force for many 
biomolecular interactions. 
The combination of hydrogen bonding, hydrophobic contacts, metal-chelation, and ionic interactions 
possesses all of the energetic and geometrical features that allow a specific network of interactions as 
the basis for the reading of the stereochemical information carried by carbohydrates through the “sugar 
code”. 
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3. THE PATH TOWARDS NEW ANTIRETROVIRAL DRUGS  
 
 
Since 1980, only 32 antiretroviral drugs were approved for AIDS therapy. They target different stages 
of the HIV-1 life cycle, such as entry, reverse transcription, integration, and maturation. A 
complementary approach is now dedicated to the search of inhibitors able to prevent mucosal infection 
and transmission at primary sites of infection, since the epidemic disease has been largely maintained 
by mucosal transmission. In parallel, the same suction was considered for other viruses and bacteria, 
like SIV, Hepatitis C, Ebola, Cytomegalovirus, Dengue, SARS and Mycobacterium tuberculosis 
interacting with the same HIV target receptor, DC-SIGN.  
Although the high avidity generated by clustering low-affinity lectin with monomers into oligomeric 
structures has made it difficult to design drugs aimed at disrupting protein-carbohydrate interactions, 
the unusually high affinity between the monomeric DC-SIGN CRDs and high-mannose 
oligosaccharides suggests that they may be useful targets. So, the latest researches on inhibitory 
mechanism for the DC-SIGN-virus interactions are described after a brief analysis of preventive and 
post-infectious therapies already in use.  
 
3.1 Prevention with Vaccines19 
For many years now, numerous efforts were needed to develop an effective and safe vaccine against 
AIDS to limit viral transmission. The use of live attenuated viruses is not feasible in humans for safety 
concerns. Vaccines based on protein subunits are scarcely immunogenic, probably because as the host 
has glycosylated many cellular proteins, its immune system is unlikely to react to the viral carbohydrate 
sites, thereby providing a different mechanism to bypass the host’s immune protection. So, other 
approaches are based on DNA vaccines or live recombinant vectors encoding HIV-1 antigens to 
enhance cell mediated immunity (CMI). For individuals already infected with HIV-1, highly active 
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antiretroviral therapy (HAART) exists thanks to the extensive development of small molecular weight 
compounds targeting some key viral processes, such as reverse transcription or protease-dependent 
Gag-Pol precursor protein cleavage (the major targets of HAART).
20
 
An important component of any HIV-1 vaccine approach is however the viral envelope glycoproteins 
(Env), the major target for neutralizing antibodies (Nabs). The use of monomeric gp120 or peptides 
derived from the immunodominant V3 loop of gp120 generates type-specific antibodies, but not 
broadly Nabs. This is likely due to occlusion of conserved V3 epitopes on most circulating isolates. 
The failure of gp120 to elicit efficiently NAbs has moved design efforts to engineering soluble versions 
with modified structure of the Env spike to recapitulate properties of the functional trimer. But, clinical 
trials (as the RV144 trial or the HVTN 505) had never demonstrated efficiently preventative effects, 
nor a decrease viral load among the vaccinees that became infected by the virus during the trial. 
 
3.2 Other Therapeutic Compounds 
Most vaccines and adjuvants are designed to induce immune responses that are stored as 
immunological memory, to rapidly recognize and clear the pathogen on subsequent exposure. But other 
numerous therapies against AIDS have been developed.  
 
For instance, an antiviral currently in use is N-
butyldeoxynojirimycin (NB-DNJ, represented in Figure 3.2), 
which has shown to be effective against a range of human 
viruses including HIV, hepatitis C virus (HCV), hepatitis B 
virus (HBV), parainfluenza, West Nile and Dengue viruses. Its activity is to inhibit the early trimming 
of the glucose moieties from Glc3Man9(GlcNAc)2 precursors in the endoplasmic reticulum. No effect 
of NB-DNJ treatment was seen on the kinetics of the interaction between gp120 and CD4. A major 
mechanism of action of NB-DNJ as an inhibitor of HIV replication is the impairment of viral entry at 
the level of post-CD4 binding, due to an effect on viral envelope components. 
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Unfortunately, the 20% of all new HIV-1 infections involve drug-resistant variants; so this could also 
happen for the NB-DNJ. The combination with nucleoside analogs as dideoxyinosine (DDI), 
dideoxycytidine (DDC), or azidothymidine (AZT) represents a valid trick and reduce also the yield of 
reverse transcriptase activity. Moreover, NB-DNJ, tested in combination with common antiretroviral, 
needs though to excessive concentrations required to achieve significant activity in vivo.
21 
Therefore the initial block of the interaction between DC and virus represents the most advantageous 
way to escape the viral infection. 
 
 
 
 
 
3.3  Synthetic Mimetic Ligands of DC-SIGN 
As already remarked, the affinity of lectins for 
monovalent carbohydrates is typically weak. DC-SIGN 
recognizes greatly oligosaccharide structures and has 
demonstrated a notably monosaccharide affinity for 
mannose. The affinity for natural oligosaccharide ligand 
such as Man9(GlcNAc)2 (showed in Figure 3.3) is a clear 
example. 
Hence, many previous studies reported the synthesis of 
multivalent carbohydrate-containing molecules and their 
inhibitor effects. These experiments were involved on different cell lines engineered to express DC-
SIGN. The oligosaccharide polymers are specifically characterized by one or many mannose regions, 
for mimicking the natural ligand Man9. In this way, the primary carbohydrate-binding site 
accommodates selectively the equatorial stereochemistry of the C3 and C4 hydroxyls found in the 
mannopyranosides.
22
 
Figure 3.3: Man9(GlcNAc)2. 
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First studies concerned monosaccharide conjugates, linked to a lipid chain of variable length, as 
represents in Figure 3.4. Their polar mannose epitope moiety binds directly to a hydrophilic linker 
essential for water solubility; the hydrophilic linker binds to turn hydrophobic saturated lipid chain. It is 
likely that, in addition to the interaction of the 
mannose unit with the CRD, the lipid chain is able 
to interact with some distinct amino acids of DC-
SIGN, thus optimizing the binding.
23
 Furthermore, it 
has been determined previously that DC-SIGN 
exists at the cell surface as a tetramer of identical 
polypeptide subunits. So in a second time, other 
findings revealed that multivalent mannose 
polymers may interfere avidly with the interaction 
between DC-SIGN and viral Env proteins as 
affirmed above. The optimized synthesis of many 
low-molecular-weight compounds gives efficient access to hyperbranched dendritic polymers (one of 
these represented in Figure 3.4), glyco-dendrimers and glycodendropeptides. The polymerization 
technique has allowed the binding of more mannose residues (represented in their chair shapes in the 
Figure 3.5) to a complex branched structure, sometimes characterized by a carrier protein.   
 
Figure 3.4 Monosaccharide conjugates. 
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It's important to clarify that high affinity of the glycoconjugate molecules requires a saccharide portion 
(mono, di- or tri-saccharide) that binds tightly to DC-SIGN receptor. On the opposite, the multivalent 
structures presentation is not necessary, but however important, for obtaining great binding affinity by 
monovalent compounds. Many studies have, thus, been focused only on activities of low-molecular-
weight mannose based glycomimetics. Some glycoconjugates, synthesized by many working groups, 
are summarized in the following Table 2. 
YEAR OF 
PUBBLI-
CATION 
GLYCOMIMETICS DERIVATIVES 
200724 
 
 
200825 
 
 
201026 
 
 
Analogues of 
Man9(GlNAc)2 
Table 2 
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3.2.1 Structural Characterization of Pseudo-Mannobiosides 
The design of glycomimetic structures is strongly influenced by the natural ligand of DC-SIGN in 
terms of valence, topology and density of carbohydrates. Man9 presents in all its arms terminal 
disaccharides Manα1-2Man which are involved in high mannose recognition process. Thus, many 
studies demonstrated that unbranched Manα1-2Man-terminated oligosaccharides bind to DC-SIGN 
almost as efficiently as the entire Man9. Moreover, the inhibitor activity of modified synthetic 
analogues was tested in vitro (paragraph 3.2.3). 
The main features of these 1,2-mannobioside mimics are a 
mannose unit with free hydroxyl groups, connected to a flexible 
cyclohexane-based aglycon (Figure 3.6), from which drifts the 
name of Pseudo-1,2-mannobioside
28
 . The cyclohexane portion 
acts as a mimic of a reducing end mannose residue and features a 
spacer-arm terminated with amino (Figure 3.6) or azido 
functionality, useful to generate multivalent DC-SIGN ligands. 
The resulting pseudo-1,2-mannobioside has the same 
conformational behavior as the natural disaccharide (Table 2, 
compound 15), but exhibits also improved stability towards the 
activity of jack-bean mannosidase.  
201327 
 
 
Figure 3.6 Compound 14, 
chemical structure of 1’-
aminooethyloxi-pseudo-1,2-
mannobioside. 
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Recent studies
27
, carried out by the same teamwork, show that a strongly DC-SIGN affinity occurs if 
the R- groups in the position 4’ and 5’ of the referent compound 2 (Table 2) are lipophilic, for example 
an aromatic ring.  However, most compounds of this recent series possess a low solubility in aqueous 
media, which limits their applicability. Subsequently, modification of the two ester moieties of the 
pseudodisaccharide 14 into amides generated glycomimetic ligands with increased activity and a 
growing water solubility. These molecules provided interesting leads, which could be improved by 
optimizing the nature of the benzylamide substituents and of appendage in the anomeric position. 
First, many types of benzylamine functionalities were replaced during synthetic studies and the relevant 
benzylamides were tested in adhesion assay. Among them, the best substituent of aromatic portion has 
proved to be a hydroxymethylene group in para position, which appears to play a role as H-bond 
acceptor. The corresponding methyl ether shows the same inhibitory potency; indeed additional 
lipophilic groups in the proximity of the acceptor (-OH) or fluorine atoms on the aromatic ring don’t 
improve the affinity.  On the other hand, two methoxy substituents in meta to the hydroxymethylene 
group had a negative effect, maybe for a different orientation of the aromatic ring around the N-
benzylic bond.  Their synthesis follows the same procedure of the choosy synthesis of para-
hydroxymethyl-bis(benzylamide), represented in the following Scheme 3.1.  
Scheme 3.1 
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Starting from enantiomerically pure (1S, 2S)-diacid 5, the bis(para-nitrophenylester) was synthesized 
and the double bond oxidized by using MCPBA (meta-chloroperbenzoic acid), to afford epoxide 6. 
Copper-catalyzed epoxide opening with azidoethanol, followed by mannosylation of alcohol 7 with 
trichloroacetemidate 8 afforded the pseudodisaccharide 9 in only four steps and with 42 % overall 
yield. The two activated p-nitrophenyl esters, used as acid-protecting groups throughout the sequence 
so far, were transformed into amides by reaction with an excess of the appropriate benzylamine (i) 
step) yielding bis(amides) 4 after Zemplén deprotection of the sugar. 
 
3.2.2 Stereochemistry of Cyclohexane Scaffold 
In parallel to the previous studies, a diastereoisomer of the compound 4 (Figure 3.7) with the opposite 
configuration (1R, 2R) of the cyclohexane ring was synthesized.  
Figure 3.7 Diastereoisomer of the compound 4 with the opposite configuration (1R, 2R). 
Its synthesis
27b
 starts from the (1R,2R)-enantiomer of 5 (Scheme 3.1) and its analysis of 
1
H NMR 
spectra confirms that all compounds share the same chair conformation of the cyclohexane ring 
observed in similar compound 2. But the relevant pseudodisaccharide didn’t demonstrate tightly 
binding to DC-SIGN, showing that the stereochemistry of the pseudodisaccharide scaffold (like to 
compound 2) is important to optimize interaction with the receptor. Only one of analogues synthetized 
by Professor Anna Bernardi team demonstrates to be the most potent inhibitor (IC50 of 31µm), 
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represented by a divalent macrocyclic ligand (1:1 mixture of isomers), shown in Table 2 (compound 
11). Therefore, it is still under consideration due to the low yield with which it was synthetized (18%). 
 
3.2.3 NMR, Docking and Infection studies  
Among the compounds mentioned above, the first to be analyzed were the ester derivatives (compound 
14 of Table 2). Its interaction with the extracellular domain of DC-SIGN was studied by NMR 
spettroscopy at 600 MHz. The Saturation Transfer Difference (STD) and the transferred nuclear 
Overhauser enhancement (TR-NOESY) experiments were also used to observe selectively the binding 
event of compound 2, substituted with the azido group instead of the amino in the anomeric position, as 
showed in Figure 3.6. They confirmed that the binding occurred and that the ligand was in close 
contact with the protein. 
A model of the DC-SIGN-compound 2 complex was obtained by docking studies, starting from the 
PDB structure of the DC-SIGN-Man4 complex (PDB code IL4).
29
 In the QM-polarized ligand docking 
protocol, ligands are docked with Glide (Grid-based Ligand Docking with Energetics), then charges on 
the ligand induced by the protein are calculated and a set of the best ligand poses are redocked. This 
protocol aims to improve the partial charges on the ligand atoms by replacing them with charges 
derived from quantum mechanical calculations on the ligand in the field of the receptor. Bernardi 
working group, which synthetized compound 2 and analogues, discovered two rapidly interconverting 
conformations of the pseudomannobiosides in water solution, the stacked (S) and extended (E) 
conformations. These two conformations were used as starting points for the docking run. All 
complexes obtained appeared to maintain the interactions between the Ca
2+
 atom and two hydroxyl 
groups of the nonreducing end mannose unit. 
Finally, infection studies were developed on pseudotype Ebola virus and Jurkat cells, expressing DC-
SIGN. The activity of compound 14 in this infection model was compared with the natural disaccharide 
derivative, presenting the amino-ethoxy linker at the anomeric position (C2’-O-CH2CH2NH2). The 
obtained results showed an IC50 of 1.91 mM for the natural disaccharide, value three times higher than 
the IC50 of the mimic (0.62 mM). This biological model showed that the designed pseudodisaccharide 
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14 is a stronger inhibitor than the corresponding disaccharide and taking into account its enzymatic 
stability could be considered as a promising candidate to prepare multivalent systems to be used as 
inhibitors of viral infection.
30 
In line with previous findings, similar studies on the benzylic bis(amide) derivatives of general formula 
4 (Table 2) were carried out. Since NMR interaction studies of compound 4 showed some overlapping 
of key signals, a better substrate as its triazole analogue was examined. It proved to be a good lead 
compound for the analysis. But only its comparison with NMR spectroscopic analysis and STD 
experiments of methyl ester referent (compound 2) confirmed the same binding mode of two 
molecules. Really recent structural analysis of the X-ray structure (Figure 3.8, a)) showed that the 
methyl ester groups of compound 2 in the complex extend towards the DC-SIGN surface in an area in 
which larger substituents can be accommodated. Larger groups in this position can be expected to reach 
the protein surface and make additional contacts: binding occurs through coordination of the calcium 
ion by OH-3 and OH-4 of the mannose residue in an orientation which allows the cyclohexane ring to 
establish a van der Waals contact with the V351 side chain of the receptor; this results in important STD 
signals for the mannose moiety and for all cyclohexane protons. Moreover, Docking studies (Figure 
3.8, b)) suggested that H-bond donors and acceptors out of the plane of the aromatic ring could be 
beneficial for interaction with the protein surface.  
This consideration, together with water solubility and synthetic availability, drove the selection of 
benzylamines used in synthetic procedures.  These molecules were tested for their activity as DC-SIGN 
ligands by using an SPR (Surface Plasmon Resonance) competition assay. Selectivity against Langerin 
was also addressed and none of the tested compounds were luckily able to fully inhibit Langerin 
binding to the surface. 
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Figure 
3.8 a) X-ray structure of the DC-SIGN/2 complex; b) Docked pose of 13 that qualitatively accounts for the STD 
data. 
As a result, high saturation in the SDT analysis and great specificity towards DC-SIGN suggested the 
improved potency of the bis(amides) over the parent dimethyl ester thanks to lipophilic interactions 
between the aromatic groups of the ligand and the binding site of DC-SIGN. 
 
3.4  Adjuvant of vaccines 
Until 2013, DC-SIGN ligands activity was considered only that of inhibition versus target receptor.
31
 
In an attempt to develop new approaches to vaccine design, many compounds like known receptor 
ligands or selected antigens could instead exert their effects upon interacting with the innate immune 
system. Activation of the innate immunity plays a central role in initiating and shaping the adaptive 
immune response, inducing thus the generation of cytokines, chemokines, and co-stimulatory 
molecules.  
The new adjuvants discovery aims to search for compounds that enhance the vaccine efficiency, even 
without a clear understanding of how they worked.
32 
For instance, analogues of some toll like receptors 
(TLRs) ligands are already used in licensed vaccines or are in advanced stages of development, 
providing a starting point for design of such therapeutics. 
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DC-SIGN activation induces interestingly the stimulation of signal transduction pathways resulting in 
TLRs signaling, the modulation of immune responses and T cell polarization, with different outcomes 
depending on the nature of the ligand involved. In the last decade, working group of Milan have 
nourished much enthusiasm into the field of adjuvant research. They focused on adjuvants interacting 
with C-type lectin receptors (CLRs), which may be an alternative or complementary to adjuvants 
targeting TRLs.  
Since the function of DC-SIGN is to bind to diverse mannose structures, they have recently 
demonstrated that a multivalent pseudo-mannosylated compound, Polyman 19 (Figure 3.9) interacts 
specifically with the carbohydrate-recognition domain of DC-SIGN. It and its glycomimetic derivatives 
inhibit DC-SIGN mediated HIV-1 infection of cellular and tissue models by competing with the 
binding of the virus to the receptor.
33
 
Polyman 19 (PM 19) is a hexavalent dendrimer carrying six units of a bisamide-based DC-SIGN 
ligand. The PM 19 efficacy in inhibiting HIV-1 infection was further evaluated exploiting a cervical 
tissue model. It completely inhibits HIV-1 Bal trans infection of CD4
+ 
T cells at 10 μM, and reduces 
the infection by 50% at 1 μM. PM 19 proved to be more effective than other compounds tested before 
2013, such as tetravalent dendron 12, that needed higher concentration to inhibit CD4 T cells trans 
infection. 
Figure 3.9 PM19 as adjuvant of vaccines 
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In principle, the multivalent structure of these Polyman allows direct conjugation with antigens, 
realizing a mixed multivalent dendrimers carrying the suitable DC-SIGN ligands and the desired 
antigen. So this covalent conjugation creates a double effect: DC-SIGN ligands, binding to the 
receptor, are addressed to endo-lysosomal pathway and then presented on major histocompatibility 
complex of class II (MHC II) and, in the other hand, the kinked antigen also enhance MHC I 
presentation through an unknown cross presentation pathway.  
The efficacy in inhibiting viral infection by PM 19 and polymannosylated ligands should be further 
investigated. In addition to the characterization of their role, the purpose of many ongoing studies is to 
expand the structure knowledge to improve the interactions with the target receptors, DC-SIGN.
25/27a
  
 
